HSV-1 amplicon vectors that direct the in situ production of foot-and-mouth disease virus antigens in mammalian cells can be used for genetic immunization

Vaccine

Volumn 28, Issue 46, 2010, Pages 7363-7372

  D'Antuono, Alejandra ^a   Laimbacher, Andrea S ^b   La Torre, Jose ^a   Tribulatti, Virginia ^c   Romanutti, Carina ^a   Zamorano, Patricia ^d   Quattrocchi, Valeria ^d   Schraner, Elisabeth M ^b   Ackermann, Mathias ^b   Fraefel, Cornel ^b   Mattion, Nora ^a  

^a Centro de Virologia Animal   (Argentina)

^b UNIVERSITY OF ZURICH   (Switzerland)

^c INSTITUTO DE INVESTIGACIONES BIOTECNOLÓGICAS   (Argentina)

^d INSTITUTO NACIONAL DE TECNOLOGÍA AGROPECUARIA INTA   (Argentina)

Author keywords

FMDV; Genetic vaccine; HSV 1 amplicon vectors; VLPs

Indexed keywords

CAPSID PROTEIN; HSV P12A3C VECTOR; UNCLASSIFIED DRUG; VIRUS ANTIGEN; VIRUS VECTOR;

AMPLICON; ANIMAL CELL; ANTIBODY DETECTION; ANTIGEN EXPRESSION; ARTICLE; CONTROLLED STUDY; DRUG SAFETY; FOOT AND MOUTH DISEASE; FOOT AND MOUTH DISEASE VIRUS; GENE CONSTRUCT; GENE EXPRESSION; GENETIC CODE; GENETIC IMMUNIZATION; HERPES SIMPLEX VIRUS 1; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNITY; IN SITU HYBRIDIZATION; MAMMAL CELL; MOLECULAR CLONING; NONHUMAN; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VERO CELL; VIREMIA; VIRUS CAPSID; VIRUS LIKE AGENT; VIRUS PARTICLE;

ANIMALS; ANTIBODIES, VIRAL; ANTIGENS, VIRAL; CAPSID PROTEINS; CERCOPITHECUS AETHIOPS; FOOT-AND-MOUTH DISEASE; FOOT-AND-MOUTH DISEASE VIRUS; GENETIC VECTORS; HEK293 CELLS; HERPESVIRUS 1, HUMAN; HUMANS; MICE; MICE, INBRED BALB C; TRANSGENES; VACCINES, DNA; VERO CELLS; VIRAL VACCINES;

EID: 77958197691     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.09.011     Document Type: Article

References (32)

1. Cuchet D., Potel C., Thomas J., Epstein A.L. HSV-1 amplicon vectors: a promising and versatile tool for gene delivery. Expert Opin Biol Ther 2007, 7:975-995.
2. Oehmig A., Fraefel C., Breakefield X.O. Update on herpesvirus amplicon vectors. Mol Ther 2004, 10:630-643.
3. Saeki Y., Ichikawa T., Saeki A., Chiocca E.A., Tobler K., Ackermann M., et al. Herpes simplex virus type 1 DNA amplified as bacterial artificial chromosome in Escherichia coli: rescue of replication-competent virus progeny and packaging of amplicon vectors. Hum Gene Ther 1998, 9:2787-2794.
4. Hocknell P.K., Wiley R.D., Wang X., Evans T.G., Bowers W.J., Hanke T., et al. Expression of human immunodeficiency virus type 1 gp120 from herpes simplex virus type 1-derived amplicons results in potent, specific, and durable cellular and humoral immune responses. J Virol 2002, 76:5565-5580.
5. Cao Y., Lu Z., Sun J., Bai X., Sun P., Bao H., et al. Synthesis of empty capsid-like particles of Asia I foot-and-mouth disease virus in insect cells and their immunogenicity in guinea pigs. Vet Microbiol 2009, 137:10-17.
6. Rueckert R.R. Picornaviruses and their replication. Fields virology 1990, 507-548. Lippincott Williams & Wilkins, Philadelphia. B.N. Fields, D.P. Knipe, R.M. Chanock (Eds.).
7. Acharya R., Fry E., Stuart D., Fox G., Rowlands D., Brown F. The three-dimensional structure of foot-and-mouth disease virus at 2.9A resolution. Nature 1989, 337:709-716.
8. Lea S., Hernandez J., Blakemore W., Brocchi E., Curry S., Domingo E., et al. The structure and antigenicity of a type C foot-and-mouth disease virus. Structure 1994, 2:123-139.
9. Abrams C.C., King A.M., Belsham G.J. Assembly of foot-and-mouth disease virus empty capsids synthesized by a vaccinia virus expression system. J Gen Virol 1995, 76(Pt 12):3089-3098.
10. Rowlands D.J., Sangar D.V., Brown F. A comparative chemical and serological study of the full and empty particles of foot-and mouth disease virus. J Gen Virol 1975, 26:227-238.
11. Grubman M.J., Morgan D.O., Kendall J., Baxt B. Capsid intermediates assembled in a foot-and-mouth disease virus genome RNA-programmed cell-free translation system and in infected cells. J Virol 1985, 56:120-126.
12. Mattion N., Konig G., Seki C., Smitsaart E., Maradei E., Robiolo B., et al. Reintroduction of foot-and-mouth disease in Argentina: characterisation of the isolates and development of tools for the control and eradication of the disease. Vaccine 2004, 22:4149-4162.
13. Grubman M.J. Development of novel strategies to control foot-and-mouth disease: marker vaccines and antivirals. Biologicals 2005, 33:227-234.
14. Lewis S.A., Morgan D.O., Grubman M.J. Expression, processing, and assembly of foot-and-mouth disease virus capsid structures in heterologous systems: induction of a neutralizing antibody response in guinea pigs. J Virol 1991, 65:6572-6580.
15. Li Z., Yi Y., Yin X., Zhang Z., Liu J. Expression of foot-and-mouth disease virus capsid proteins in silkworm-baculovirus expression system and its utilization as a subunit vaccine. PLoS One 2008, 3:e2273.
16. Grubman M.J., Lewis S.A., Morgan D.O. Protection of swine against foot-and-mouth disease with viral capsid proteins expressed in heterologous systems. Vaccine 1993, 11:825-829.
17. Mayr G.A., Chinsangaram J., Grubman M.J. Development of replication-defective adenovirus serotype 5 containing the capsid and 3C protease coding regions of foot-and-mouth disease virus as a vaccine candidate. Virology 1999, 263:496-506.
18. Smith I.L., Hardwicke M.A., Sandri-Goldin R.M. Evidence that the herpes simplex virus immediate early protein ICP27 acts post-transcriptionally during infection to regulate gene expression. Virology 1992, 186:74-86.
19. Fussenegger M., Moser S., Bailey J.E. pQuattro vectors allow one-step multigene metabolic engineering and auto-selection of quattrocistronic artificial mammalian operons. Cytotechnology 1998, 28:229-235.
20. Fraefel C., Song S., Lim F., Lang P., Yu L., Wang Y., et al. Helper virus-free transfer of herpes simplex virus type 1 plasmid vectors into neural cells. J Virol 1996, 70:7190-7197.
21. Saeki Y., Fraefel C., Ichikawa T., Breakefield X.O., Chiocca E.A. Improved helper virus-free packaging system for HSV amplicon vectors using an ICP27-deleted, oversized HSV-1 DNA in a bacterial artificial chromosome. Mol Ther 2001, 3:591-601.
22. Aarthi D., Ananda Rao K., Robinson R., Srinivasan V.A. Validation of binary ethyleneimine (BEI) used as an inactivant for foot and mouth disease tissue culture vaccine. Biologicals 2004, 32:153-156.
23. Seki C., Robiolo B., Periolo O., Iglesias M., D'Antuono A., Maradei E., et al. Rapid methodology for antigenic profiling of FMDV field strains and for the control of identity, purity and viral integrity in commercial virus vaccines using monoclonal antibodies. Vet Microbiol 2009, 133:239-251.
24. Lopez O.J., Sadir A.M., Borca M.V., Fernandez F.M., Braun M., Schudel A.A. Immune response to foot-and-mouth disease virus in an experimental murine model. II. Basis of persistent antibody reaction. Vet Immunol Immunopathol 1990, 24:313-321.
25. Piatti P.G., Berinstein A., Lopez O.J., Borca M.V., Fernandez F., Schudel A.A., et al. Comparison of the immune response elicited by infectious and inactivated foot-and-mouth disease virus in mice. J Gen Virol 1991, 72(Pt 7):1691-1694.
26. Carrillo C., Wigdorovitz A., Oliveros J.C., Zamorano P.I., Sadir A.M., Gomez N., et al. Protective immune response to Foot and Mouth Disease Virus with VP1 expressed in transgenic plants. J Virol 1998, 72(2):1688-1690.
27. Martinez-Salas E., Domingo E. Effect of expression of the aphthovirus protease 3C on viral infection and gene expression. Virology 1995, 212:111-120.
28. Santos K., Duke C.M., Rodriguez-Colon S.M., Dakwar A., Fan S., Keefer M.C., et al. Effect of promoter strength on protein expression and immunogenicity of an HSV-1 amplicon vector encoding HIV-1 Gag. Vaccine 2007, 25:1634-1646.
29. McKendall R.R., Woo W. Antibody activity to herpes simplex virus in mouse Ig classes and IgG subclasses. Arch Virol 1988, 98:225-233.
30. McKendall R.R., Woo W. Murine IgG subclass responses to herpes simplex virus type 1 and polypeptides. J Gen Virol 1988, 69(Pt 4):847-857.
31. Logvinoff C., Epstein A.L. A novel approach for herpes simplex virus type 1 amplicon vector production, using the Cre-loxP recombination system to remove helper virus. Hum Gene Ther 2001, 12:161-167.
32. Zaupa C., Revol-Guyot V., Epstein A.L. Improved packaging system for generation of high-level noncytotoxic HSV-1 amplicon vectors using Cre-loxP site-specific recombination to delete the packaging signals of defective helper genomes. Hum Gene Ther 2003, 14:1049-1063.